Trade Curis, Inc. - CRIS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1348 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.9176 |
| Open | 3.7276 |
| 1-Year Change | -30.56% |
| Day's Range | 3.4876 - 3.9376 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 3.9376 | 0.1400 | 3.69% | 3.7976 | 3.9476 | 3.4676 |
| Nov 14, 2024 | 3.9176 | 0.0000 | 0.00% | 3.9176 | 4.0176 | 3.9176 |
| Nov 13, 2024 | 3.8076 | -0.2900 | -7.08% | 4.0976 | 4.1876 | 3.6576 |
| Nov 12, 2024 | 3.9976 | -0.2000 | -4.76% | 4.1976 | 4.2676 | 3.9676 |
| Nov 11, 2024 | 4.2676 | -0.1800 | -4.05% | 4.4476 | 4.4476 | 4.0676 |
| Nov 8, 2024 | 4.2876 | -0.0100 | -0.23% | 4.2976 | 4.3576 | 4.0876 |
| Nov 7, 2024 | 4.2276 | 0.0900 | 2.18% | 4.1376 | 4.3276 | 3.9876 |
| Nov 6, 2024 | 4.1176 | -0.3900 | -8.65% | 4.5076 | 4.5076 | 3.9376 |
| Nov 5, 2024 | 4.3476 | 0.1600 | 3.82% | 4.1876 | 4.9076 | 4.0376 |
| Nov 4, 2024 | 4.2376 | 0.0800 | 1.92% | 4.1576 | 4.2476 | 3.9576 |
| Nov 1, 2024 | 4.0876 | -0.1000 | -2.39% | 4.1876 | 4.1876 | 4.0876 |
| Oct 31, 2024 | 4.1976 | -0.1500 | -3.45% | 4.3476 | 4.7076 | 4.1776 |
| Oct 30, 2024 | 4.3876 | -0.0600 | -1.35% | 4.4476 | 4.4976 | 4.0976 |
| Oct 29, 2024 | 4.5676 | -0.1700 | -3.59% | 4.7376 | 4.7376 | 4.2276 |
| Oct 28, 2024 | 4.8376 | -0.0200 | -0.41% | 4.8576 | 4.9176 | 4.7376 |
| Oct 25, 2024 | 4.9376 | -0.1900 | -3.71% | 5.1276 | 5.1876 | 4.8476 |
| Oct 24, 2024 | 5.0976 | 0.0700 | 1.39% | 5.0276 | 5.2076 | 5.0276 |
| Oct 23, 2024 | 5.1076 | -0.1100 | -2.11% | 5.2176 | 5.2276 | 5.0776 |
| Oct 22, 2024 | 5.2876 | 0.0900 | 1.73% | 5.1976 | 5.3376 | 5.0476 |
| Oct 21, 2024 | 5.1276 | -0.0300 | -0.58% | 5.1576 | 5.2176 | 5.1076 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Curis, Inc. Company profile
About Curis, Inc.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Equity composition
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.
| Industry: | Biotechnology & Medical Research (NEC) |
128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com